CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 42 enrolled
Drug / intervention
Ketamine +1 moredrug
Likely dose
Ketamine 0.25 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00978757
NCT00978757Phase 4Completed
CompareCT.gov

Phase 4: Study of Ketamine Inhibition of Interleukin 6 in Hepatic Resections Requiring Temporary Porto-arterial Occlusion

Hospital Italiano de Buenos Aires·interventional·Posted Sep 17, 2009·Updated Jan 15, 2019

In Brief

A Phase 4 clinical trial evaluating Ketamine and Placebo for Hepatectomy. Completed, enrolled 42 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether ketamine is effective to inhibit interleukin 6 synthesis in hepatic resections requiring temporary porto-arterial occlusion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatectomy
CountriesArgentina
Collaborators--

Timeline

Phase 4CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 17, 2009
Enrollment StartJun 1, 2001
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 16.8 years ago

Interventions

Ketaminedrug

Ketamine: 0.25 mg/kg, intravenously, one dose.

Placeboother

saline solution